21 September 2026
TMC-I Regimen May Expand Treatment Access in Advanced Head and Neck Cancer
Source: The ASCO Post.
This research from India is particularly interesting because it addresses both treatment effectiveness and affordability.
A Phase III clinical trial involving 422 patients investigated a combination called TMC-I, consisting of:
Low-dose nivolumab (immunotherapy).
Methotrexate.
Erlotinib.
Celecoxib.
The results were encouraging:
Outcome
TMC-I
Comparison chemotherapy
Median overall survival
10.3 months
6.2 months
One-year survival
46%
23%
Tumour response rate
53.4%
24.1%
Median progression-free survival
5.5 months
2.7 months
The TMC-I group also experienced fewer serious treatment-related side effects.
The researchers highlighted the potential for this treatment to be more affordable and accessible in countries where conventional immunotherapy is prohibitively expensive.
Why this matters: Innovation is not just about developing new medicines. It is also about making effective treatments more accessible to people regardless of where they live or their ability to pay.
